Patents Assigned to City of Hope
  • Patent number: 11357565
    Abstract: A hand tool has a pivot connection pivotally attaching a first arm to a second arm, with the pivot connection fixed relative to the first arm and movable to first and second positions relative to the second arm. A spring urges the pivot connection into the first position. When jaws on the front ends of the arms clamp tissue with force greater than a pre-set threshold, the spring force is overcome and the jaws may move linearly apart, allowing for more uniform clamping of the tissue. The first arm may have an arm spring extending between a front segment pivotally attached to a rear segment of the first arm.
    Type: Grant
    Filed: November 1, 2018
    Date of Patent: June 14, 2022
    Assignee: City of Hope
    Inventor: Gagandeep Singh
  • Patent number: 11345656
    Abstract: Described herein, inter alia, are compositions of PCNA modulators and methods for treating or preventing cancer.
    Type: Grant
    Filed: December 1, 2020
    Date of Patent: May 31, 2022
    Assignee: City of Hope
    Inventors: Linda H. Malkas, David Horne, Robert J. Hickey, Long Gu
  • Publication number: 20220143174
    Abstract: Disclosed are vaccine compositions comprising a single KSHV-LP comprising two or more KSHV glycoproteins and/rl or one or more T cell antigens and methods of preventing or treating KSHV infections using the vaccine compositions. Also disclosed is an expression system or a single expression vector for co-expressing two or more KSHV glycoproteins simultaneously to generate a vaccine comprising a single virus-like particle. The expression system may include a single plasmid inserted with two or more nucleic acid sequences that encode two or more KSHV glycoproteins linked by one or more linking sequences such that the KSHV glycoproteins are co-expressed simultaneously.
    Type: Application
    Filed: February 21, 2020
    Publication date: May 12, 2022
    Applicant: CITY OF HOPE
    Inventors: Javier Gordon OGEMBO, Lorraine Zvichapera MUTSVUNGUMA, David H. MULAMA, Murali MUNIRAJU
  • Patent number: 11324731
    Abstract: Disclosed herein, inter alia, are compounds and methods for inhibiting the thioredoxin-thioredoxin-interacting-protein (TXNIP-TRX) complex.
    Type: Grant
    Filed: September 13, 2019
    Date of Patent: May 10, 2022
    Assignee: CITY OF HOPE
    Inventors: Rama Natarajan, Feng Miao, Nagarajan Vaidehi, Supriyo Bhattacharya, Adrien Beau Larsen
  • Patent number: 11311622
    Abstract: In one embodiment, a masked monoclonal antibody (mAb) is provided, the mAb, encoded by a nucleic acid sequence or an amino acid sequence molecule comprising a signal sequence, a masking epitope sequence, a linker sequence that is cleavable by a protease specific to a target tissue; and an antibody or a functional fragment thereof. In another embodiment, a masked monoclonal antibody (mAb) is provided, which includes a therapeutic mAb and a mask, the mask comprising protein A and protein L attached by a protease cleavable linker.
    Type: Grant
    Filed: July 2, 2019
    Date of Patent: April 26, 2022
    Assignees: City of Hope, Thomas Jefferson University
    Inventors: John C. Williams, Cindy Zer, Kendra N. Avery, Ulrich Rodeck, Joshua M. Donaldson, Csaba Kari
  • Patent number: 11311608
    Abstract: Autophagy is the principal catabolic response to nutrient starvation. However, excessive autophagy can be cytotoxic or cytostatic, and contribute to cell death, but its mechanism of induction remains elusive. Here, it was demonstrated that prolonged arginine starvation by ADI-PEG20 induced an autophagy-dependent death of argininosuccinate synthetase 1 (ASS1)-deficient breast cancer cells. Consequently, arginine depleting agents such as ADI-PEG20 may be used in methods for killing one or more argininosuccinate synthetase 1 (ASS1)-deficient breast cancer cells. Further, abundance of ASS1 was either low or absent in more than 60% of 149 random breast cancer biosamples, which could be exploited as candidates for arginine starvation therapy.
    Type: Grant
    Filed: April 1, 2016
    Date of Patent: April 26, 2022
    Assignee: CITY OF HOPE
    Inventors: David K. Ann, Yun-Ru Chen, Fuming Qiu
  • Patent number: 11306329
    Abstract: Provided herein are adeno-associated virus (AAV) compositions that can restore F8 gene function in a cell without co-transducing or co-administering an exogenous nuclease or a nucleotide sequence that encodes an exogenous nuclease. Also provided are methods of using the AAV compositions to correct an F8 gene mutation and/or treat a disease or disorder associated with an F8 gene mutation. Packaging systems for making the adeno-associated virus compositions are also provided.
    Type: Grant
    Filed: February 19, 2019
    Date of Patent: April 19, 2022
    Assignees: CITY OF HOPE, HOMOLOGY MEDICINES, INC.
    Inventors: Saswati Chatterjee, Laura Jane Smith, Jeff Lynn Ellsworth, Hillard Rubin, Jason Boke Wright, James Anthony McSwiggen
  • Patent number: 11306072
    Abstract: Disclosed herein inter alia are compositions and methods for treating cancer using 5-Br-indirubin derivatives.
    Type: Grant
    Filed: February 13, 2020
    Date of Patent: April 19, 2022
    Assignees: City of Hope, National and Kapodistrian University of Athens
    Inventors: Richard Jove, Sangkil Nam, David Horne, Jun Xie, Alexios Leandros Skaltsounis, Marina Kritsanida, Nicolas Gaboriaud-Kolar
  • Patent number: 11278594
    Abstract: The present invention relates to chimeric transmembrane immunoreceptors, named “zetakines,” comprised of an extracellular domain comprising a soluble receptor ligand linked to a support region capable of tethering the extracellular domain to a cell surface, a transmembrane region and an intracellular signalling domain. Zetakines, when expressed on the surface of T lymphocytes, direct T cell activity to those specific cells expressing a receptor for which the soluble receptor ligand is specific. Zetakine chimeric immunoreceptors represent a novel extension of antibody-based immunoreceptors for redirecting the antigen specificity of T cells, with application to treatment of a variety of cancers, particularly via the autocrin/paracrine cytokine systems utilized by human malignancy.
    Type: Grant
    Filed: December 20, 2019
    Date of Patent: March 22, 2022
    Assignee: City of Hope
    Inventor: Michael Jensen
  • Patent number: 11279752
    Abstract: Provided herein are recombinant masking proteins and recombinant ligand proteins useful in treating cancer, neurodegenerative disease, and cardiovascular disease. The recombinant masking proteins provided herein may, inter alia, be used as non-covalent masks of antagonists of, for example, cellular growth factors (e.g., TNF) or cell surface proteins (e.g., CTLA-4).
    Type: Grant
    Filed: September 3, 2019
    Date of Patent: March 22, 2022
    Assignees: CITY OF HOPE, THOMAS JEFFERSON UNIVERSITY
    Inventors: John C. Williams, Ulrich Rodeck, Kurt Jenkins
  • Publication number: 20220072043
    Abstract: Described are improved methods for treating solid tumors, such as malignant gliomas, with a dual approach utilizing a CAR-T immunotherapy and a viral oncolytic therapy.
    Type: Application
    Filed: September 9, 2021
    Publication date: March 10, 2022
    Applicants: Mustang Bio, Inc., Beckman Research Institute of the City of Hope
    Inventors: Knut Niss, Sadik H. Kassim, Christine E. Brown, Stephen J. Forman, Behnam Badie
  • Patent number: 11266618
    Abstract: Methods of quantifying N2-carboxyethyl-2?-deoxyguanosine (CEdG) levels in biological samples and comparing those levels to known normal levels can diagnose a number of disorders, including diabetes and cancer. Methods can also determine whether therapies for disorders are effective by measuring CEdG levels before and after treatment. Measurement of CEdG levels occurs using liquid chromatography electrospray ionization tandem mass spectrometry.
    Type: Grant
    Filed: December 29, 2017
    Date of Patent: March 8, 2022
    Assignee: CITY OF HOPE
    Inventors: Samuel Rahbar, Timothy W. Synold, John Termini, Daniel Tamae, Gerald Wuenschell
  • Patent number: 11268152
    Abstract: In accordance with the present invention, the single gene SERPINA1 has been identified as a significant predictor of survival in ER+ and ER+/HER2+ breast cancer patients. For example, patients with ER+/FIER2+ breast cancer generally have a worse outcome compared to ER+/FIER2? and ER?/FIER2+ patients. Currently there is no known predictive marker for the treatment C outcome of ER+ and ER+/FIER2+ breast cancers, thus the ability of SERPINA1 to predict the survival of this intrinsic subtype of breast cancer patients is valuable.
    Type: Grant
    Filed: January 19, 2016
    Date of Patent: March 8, 2022
    Assignee: CITY OF HOPE
    Inventors: Shiuan Chen, Hei Jason Chan
  • Patent number: 11261491
    Abstract: Provided herein are, inter alia, nucleic acids, methods, and kits for detecting unmethylated DNA in body fluid sample of a subject. The disclosure includes compositions, methods, and kits for detecting unmethylation at a CpG site in an insulin gene promoter of a subject.
    Type: Grant
    Filed: July 8, 2019
    Date of Patent: March 1, 2022
    Assignee: City of Hope
    Inventors: Kevin Ferreri, Mohamed I. Husseiny Elsayed
  • Patent number: 11261449
    Abstract: Provided herein, inter alia, are compounds capable of binding HSP70 (e.g. mHSP70) on a cell and internalizing into said cell. The compositions provided herein may be useful for delivering therapeutic and diagnostic agents to a cell. Further provided are pharmaceutical compositions and methods of treatment using nucleic acid compounds provided herein.
    Type: Grant
    Filed: December 18, 2019
    Date of Patent: March 1, 2022
    Assignees: City of Hope, Apierna Ltd
    Inventors: John J. Rossi, Sorah Yoon, Nagy Habib
  • Patent number: 11246942
    Abstract: Antibodies and meditopes that bind to the antibodies are provided, as well as complexes, compositions and combinations containing the meditopes and antibodies, and methods of producing, using, testing, and screening the same, including therapeutic and diagnostic methods and uses.
    Type: Grant
    Filed: June 5, 2017
    Date of Patent: February 15, 2022
    Assignee: City of Hope
    Inventors: John C. Williams, David A. Horne, Yuelong Ma, Heng Wei Chang, Joshua Michael Donaldson, Cindy Zer, Krzysztof Bzymek, Kendra Nicole Avery, Jun Xie
  • Publication number: 20220041743
    Abstract: Provided herein are BAFF-R antibodies as well as compositions and methods of making and using the same. The antibodies provided herein are, inter alia, useful for the treatment of cancer and autoimmune diseases.
    Type: Application
    Filed: August 16, 2021
    Publication date: February 10, 2022
    Applicants: CITY OF HOPE, BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Hong QIN, Larry W. KWAK, Jingxing LI, Kexin HUANG
  • Patent number: 11242568
    Abstract: The present subject matter provides, inter alia, a method of diagnosing invasive ductal cancer or detecting invasive ductal cancer risk in a subject who has ductal carcinoma in situ, a method of treating breast cancer in a subject detected to have invasive ductal cancer or determined to be at risk of invasive ductal cancer, compositions for detecting invasive presence or potential in ductal carcinoma in situ in a subject, and kits including reagents and composition for detecting invasive presence or potential in ductal carcinoma in situ in a subject.
    Type: Grant
    Filed: December 28, 2018
    Date of Patent: February 8, 2022
    Assignee: City of Hope
    Inventors: Maria A. Hahn, John H. Yim, Yuman Fong, Arthur X. Li, Xiwei Wu, Sun-Wing T. R. Tong
  • Patent number: 11242531
    Abstract: Provided herein are, inter alia, compositions and methods for the treatment of hypercholesterolemia. The compositions include double-stranded and single-stranded RNAs capable of repressing IncRNA and concomitantly increasing LDLR activation. The compositions are useful for activating LDLR in liver cells.
    Type: Grant
    Filed: February 2, 2018
    Date of Patent: February 8, 2022
    Assignee: CITY OF HOPE
    Inventors: Kevin V. Morris, Roslyn Ray
  • Publication number: 20220031716
    Abstract: Disclosed herein are conditioning regimens and methods for inducing MHC- or HLA-mismatched mixed chimerism by conditioning a recipient with radiation-free, low-doses of cyclophosphamide (CY), pentostatin (PT), and anti-thymocyte globulin (ATG) prior to transplantation of donor bone marrow cells. In certain embodiments, the donor bone marrow cells may be CD4+ T-depleted bone marrow cells. The conditioning regimens and methods may also include administering one or more populations of conditioning donor cells selected from donor CD4+ T-depleted spleen cells, donor CD8+ T cells, and donor G-CSF-mobilized peripheral blood mononuclear cells. The conditioning regimen is clinically acceptable and can be used for treating hereditary hematological diseases and autoimmune diseases, as well as for promoting organ transplantation immune tolerance.
    Type: Application
    Filed: August 11, 2021
    Publication date: February 3, 2022
    Applicant: CITY OF HOPE
    Inventor: Defu ZENG